AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026)

AtaiBeckley's (ATAI) quarterly Cash from Financing Activities came in at $821000.0 in Q1 2026, down 98.62% year-on-year from $59.6 million in Q1 2025, and down 98.62% quarter-over-quarter from $59.6 million in Q1 2025.

AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026) Analysis & Trends

AtaiBeckley (ATAI) has 6 years of Cash from Financing Activities data on file, last reported at $59.7 million in Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 1120.76% year-over-year to $59.7 million; the trailing twelve-month figure through Sep 2025 stood at $127.3 million (up 4026.57% YoY), and the FY2024 full-year result was $5.4 million, up 164.32% from the prior year.
  • Cash from Financing Activities slipped to $821000.0 in Q1 2026 per ATAI's latest filing, from $59.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $59.6 million in Q1 2025 and bottomed at $821000.0 in Q1 2026.
  • A 5-year average of $32.6 million and a median of $1.8 million in 2022 frame the typical range for Cash from Financing Activities.
  • Across the five-year window, Cash from Financing Activities slumped 817.68% in 2023 and surged 2279.45% in 2025, its largest moves.
  • Tracing ATAI's Cash from Financing Activities over 5 years: stood at $1.7 million in 2021, then sank by 153.51% to -$922000.0 in 2022, then tumbled by 817.68% to -$8.5 million in 2023, then soared by 101.82% to $154000.0 in 2024, then surged by 38694.81% to $59.7 million in 2025.
  • Business Quant data shows ATAI's Cash from Financing Activities at $59.7 million in Q3 2025, $7.8 million in Q2 2025, and $59.6 million in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 AtaiBeckley 2.56 Bn 2.56 Bn - 59.74 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 821,000.00
Mar 31, 2026 821,000.00
Sep 30, 2025 59.74 Mn
Sep 30, 2025 59.74 Mn
Jun 30, 2025 7.76 Mn
Jun 30, 2025 7.76 Mn
Mar 31, 2025 59.61 Mn
Mar 31, 2025 59.61 Mn
Mar 31, 2025 59.61 Mn
Mar 31, 2025 59.61 Mn
Dec 31, 2024 154,000.00
Dec 31, 2024 154,000.00
Sep 30, 2024 4.89 Mn
Sep 30, 2024 4.89 Mn
Jun 30, 2024 326,000.00
Jun 30, 2024 326,000.00
Dec 31, 2023 -8.46 Mn
Dec 31, 2023 -8.46 Mn
Jun 30, 2023 -100,000.00
Jun 30, 2023 -100,000.00